Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Tarsus Pharmaceuticals Inc’s stock clocked out at $51.76, down -2.25% from its previous closing price of $52.95. In other words, the price has decreased by -$2.25 from its previous closing price. On the day, 0.54 million shares were traded. TARS stock price reached its highest trading level at $53.36 during the session, while it also had its lowest trading level at $50.95.
Ratios:
To gain a deeper understanding of TARS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.38 and its Current Ratio is at 5.42. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Neutral rating and assigned the stock a target price of $19.
On July 18, 2023, William Blair started tracking the stock assigning a Outperform rating and target price of $44.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 12 ’24 when LINK WILLIAM J PHD sold 35,000 shares for $26.08 per share. The transaction valued at 912,961 led to the insider holds 0 shares of the business.
FLYING L PARTNERS XI LLC bought 35,000 shares of TARS for $939,750 on Aug 12 ’24. On Jun 18 ’24, another insider, Farrow Jeffrey S, who serves as the insider of the company, sold 10,445 shares for $27.47 each. As a result, the insider received 286,924 and left with 18,136 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 2024116096 and an Enterprise Value of 1733381888. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.26 while its Price-to-Book (P/B) ratio in mrq is 8.32. Its current Enterprise Value per Revenue stands at 13.373 whereas that against EBITDA is -12.429.
Stock Price History:
The Beta on a monthly basis for TARS is 1.02, which has changed by 0.7858348 over the last 52 weeks, in comparison to a change of 0.21659255 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $57.28, while it has fallen to a 52-week low of $20.08. The 50-Day Moving Average of the stock is -0.23%, while the 200-Day Moving Average is calculated to be 36.78%.
Shares Statistics:
It appears that TARS traded 626.86K shares on average per day over the past three months and 463010 shares per day over the past ten days. A total of 38.20M shares are outstanding, with a floating share count of 32.56M. Insiders hold about 14.81% of the company’s shares, while institutions hold 109.25% stake in the company. Shares short for TARS as of 1736899200 were 7020304 with a Short Ratio of 11.20, compared to 1734048000 on 7543047. Therefore, it implies a Short% of Shares Outstanding of 7020304 and a Short% of Float of 19.03.
